Josep M. Miró

Sobre mi

Publicacions destacades

• Immunological and virological findings in a patient with exceptional post-treatment control: a case report

  Autors: Climent N, Ambrosioni J, González T, Xufré C, Casadellà M, Noguera-Julian M, Paredes R, Plana M, Grau-Expósito J, Mallolas J, Alcamí J, Sánchez-Palomino S, Miró JM, Hospital Clínic de Barcelona PHI investigators.

  Referència: Lancet Hiv 2023.

• Early antiretroviral therapy not associated with higher cryptococcal meningitis mortality in people with HIV in high-income countries: an international collaborative cohort study

  Autors: Ingle SM; Miro JM; May MT; Cain LE; Schwimmer C; Zangerle R; Sambatakou H; Cazanave C; Reiss P; Brandes V; Bucher HC; Sabin C; Vidal F; Obel N; Mocroft A; Wittkop L; D'arminio Monforte A; Torti C; Mussini C; Furrer H; Konopnicki D; Tiera R; Saag MS; Crane HM; Moore RD; Jacobson JM; Mathews WC; Geng E; Eron JJ; Althoff KN; Kroch A; Lang R; Gill MJ; Sterne JAC; ART-CC; COHERE in EuroCoord; CNICS and NA-ACCORD.

  Referència: Clinical Infectious Diseases 2023.

• The 2023 Duke-ISCVID Criteria for Infective Endocarditis: Updating the Modified Duke Criteria

  Autors: Fowler VG; Durack DT; Selton-Suty C; Athan E; Bayer AS; Chamis AL; Dahl A; DiBernardo L; Durante-Mangoni E; Duval X; Fortes C; Fosbøl E; Hannan MM; Hasse B; Hoen B; Karchmer AW; Mestres CA; Petti CA; Pizzi MN; Preston SD; Roque A; Vandenesch F; van der Meer JTM; van der Vaart TW; Miro JM.

  Referència: Clinical Infectious Diseases 2023.

• Clinical characteristics and outcome of infective endocarditis due to Abiotrophia and Granulicatella compared to Viridans group streptococci

  Autors: Téllez A, Ambrosioni J, Hernández-Meneses M, Llopis J, Ripa M, Chambers ST, Holland D, Almela M, Fernández-Hidalgo N, Almirante B, Bouza E, Strahilevitz J, Hannan MM, Harkness J, Kanafani ZA, Lalani T, Lang S, Raymond N, Read K, Vinogradova T, Woods CW, Wray D, Moreno A, Chu VH, Miro JM, International Collaboration on Endocarditis (ICE) Investigators.

  Referència: Journal Of Infection 2022.

• Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study

  Autors: Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Llibre JM, Domingo P, Falcó V, Imaz A, Cortés C, Force L, Letang E, Vilaró I, Casabona J, Miro JM, PISCIS study group.

  Referència: Lancet Hiv 2021.

• Infective Endocarditis in Patients on Chronic Hemodialysis

  Autors: Pericàs JM, Llopis J, Jiménez-Exposito MJ, Kourany WM, Almirante B, Carosi G, Durante-Mangoni E, Fortes CQ, Giannitsioti E, Lerakis S, Montagna-Mella R, Ambrosioni J, Tan RS, Mestres CA, Wray D, Pachirat O, Moreno A, Chu VH, de Lazzari E, Fowler VG, Miró JM, ICE Investigators.

  Referència: Journal Of The American College Of Cardiology 2021.

• Prospective Cohort Study of Infective Endocarditis in People Who Inject Drugs

  Autors: Pericàs JM, Llopis J, Athan E, Hernández-Meneses M, Hannan MM, Murdoch DR, Kanafani Z, Freiberger T, Strahilevitz J, Fernández-Hidalgo N, Lamas C, Durante-Mangoni E, Tattevin P, Nacinovich F, Chu VH, Miró JM, International Collaboration on Endocarditis (ICE) Investigators.

  Referència: Journal Of The American College Of Cardiology 2021.

• Overview of SARS-CoV-2 infection in adults living with HIV

  Autors: Ambrosioni J, Blanco JL, Reyes-Urueña JM, Davies MA, Sued O, Marcos MA, Martínez E, Bertagnolio S, Alcamí J, Miro JM, COVID-19 in HIV Investigators.

  Referència: Lancet Hiv 2021.

• Outpatient Parenteral Antibiotic Treatment (OPAT) for Infective Endocarditis: a Prospective Cohort Study From the GAMES Cohort

  Autors: Pericà S JM, Llopis J, González-Ramallo V, Goenaga MÁ, Muñoz P, García-Leoni ME, Fariñas MC, Pajarón M, Ambrosioni J, Luque R, Goikoetxea J, Oteo JA, Carrizo E, Bodro M, Reguera-Iglesias JM, Navas E, Hidalgo-Tenorio C, Miró JM, Spanish Collaboration on Endocarditis-Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES) investigators.

  Referència: Clinical Infectious Diseases 2019.

Projectes destacats

• In vitro and experimental endocarditis model study of the efficacy of new oral and parenteral combinations of antibiotics for outpatient treatment of infectious endocarditis

  Investigador/a principal: Josep M. Miró Meda

  Codi: PI20/00830

  Durada: 01/01/2021 - 31/12/2023

• Prevention of vascular catheter-related infections by the FUNctionalization of CATHeters with thermically activated hydrogels with antimicrobial agents of broad spectrum (FUNCATH).

  Investigador/a principal: Cristina Garcia de la Maria

  Codi: 75/C/2018

  Durada: 15/01/2019 - 31/12/2022

• Eficacia de nuevas pautas de tratamiento antibiótico de la endocarditis enterocócica evaluadas in vitro y en el modelo de endocarditis experimental.

  Investigador/a principal: J.M. Miró

  Codi: PI17/01251

  Durada: 01/01/2018 - 01/01/2020

• Estudio clínico y experimental de la relación entre la CMI de vancomicina en Staphylococcus aureus sensible a meticilina (SASM) y el pronóstico de la endocarditis infecciosa (EI) izquierda causada SASM

  Investigador/a principal: José María Miró Meda

  Codi: 201526 10

  Durada: 01/01/2016 - 01/01/2018

• A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients with Intravenous Catheter associated Blood Stream Infections due to Staphylococci

  Investigador/a principal: José María Miró Meda, Josep M. Miró Meda

  Codi: BAA NIAID-DMID-NIH AI 200

  Durada: 01/01/2011 - 31/12/2017